Theodore Pravinchandra Abraham, MD
Cardiovascular Disease (Cardiology) · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
Offices
2 locations · University of California San Francisco · Regents of the University of California
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Abraham’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence C147652 · Current
Licensed to practise in California · since 2017 · expires 2028-05-31 · Goa University, Goa Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$54,717
Medicare paid this office $54,717 for 515 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 281 | $16,408 | $58 |
| Long return visit (40+ min) | 61 | $14,307 | $122 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $5,801 | $123 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 50 | $3,718 | $71 |
| New patient visit (60+ min) | 16 | $2,223 | $139 |
See all 15 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 281 | $16,408 | $58 |
| Long return visit (40+ min) | 61 | $14,307 | $122 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $5,801 | $123 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 50 | $3,718 | $71 |
| New patient visit (60+ min) | 16 | $2,223 | $139 |
| Ultrasound of heart with probe in esophagus, with report | 22 | $2,026 | $92 |
| Ultrasound of heart, follow-up | 60 | $1,620 | $22 |
| Heart muscle strain imaging | 107 | $1,082 | $10 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 33 | $621 | $19 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 79 | $609 | $6 |
| Ultrasound of heart blood flow, valves and chambers | 22 | $346 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 101 | $326 | $3 |
| Heart muscle strain imaging | 12 | $320 | $27 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 20 | $311 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $247 | $12 |
Who their Medicare patients are
515 Original Medicare patients in 2024. Average age 74 · Under 65 11% · 85 and older 13% · Women 47% · Also on Medicaid 36% · Health risk score 2.33. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 48% · Heart failure 46% · Atrial fibrillation 42% · Diabetes 41% · Chronic kidney disease 40% · Depression 27% · Cancer 20% · COPD 19% · Stroke 17% · Dementia 10%.
The office billed $877,620, Medicare allowed $71,391 and paid $54,717; for 1,128 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 515 | 1,128 | 74 | 2.33 | $877,620 | $54,717 |
| 2023 | 410 | 828 | 74 | 1.99 | $707,157 | $41,801 |
| 2022 | 498 | 865 | 73 | 2.06 | $774,747 | $44,750 |
| 2021 | 549 | 866 | 73 | 2.08 | $777,250 | $52,343 |
| 2020 | 393 | 656 | 72 | 2.33 | $525,396 | $35,966 |
| 2019 | 735 | 1,019 | 72 | 2.19 | $733,317 | $52,896 |
| 2018 | 622 | 935 | 72 | 2.40 | $545,403 | $44,688 |
| 2017 | 893 | 1,494 | 69 | 2.86 | $349,183 | $41,862 |
| 2016 | 1,389 | 2,556 | 69 | 2.53 | $310,164 | $46,939 |
| 2015 | 1,057 | 1,720 | 69 | 2.57 | $215,292 | $35,482 |
| 2014 | 1,205 | 1,980 | 68 | 2.48 | $209,627 | $34,173 |
| 2013 | 867 | 1,490 | 69 | 2.56 | $187,494 | $28,946 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 222 | $12,682 | $56 |
| Long return visit (40+ min) | 57 | $10,326 | $120 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 36 | $4,032 | $112 |
| Ultrasound of heart with probe in esophagus, with report | 31 | $2,857 | $92 |
| New patient visit (60+ min) | 17 | $2,595 | $153 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 26 | $1,926 | $74 |
| Ultrasound of heart, follow-up | 32 | $936 | $22 |
| Heart muscle strain imaging | 71 | $721 | $10 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 14 | $699 | $50 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 29 | $573 | $19 |
| Ultrasound of heart blood flow, valves and chambers | 31 | $494 | $16 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 43 | $348 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 23 | $300 | $13 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 75 | $241 | $3 |
2022: 15 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 307 | $18,496 | $59 |
| Long return visit (40+ min) | 36 | $7,694 | $124 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 39 | $2,863 | $72 |
| Ultrasound of heart with probe in esophagus, with report | 30 | $2,787 | $90 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $2,283 | $59 |
| New patient visit (60+ min) | 11 | $1,782 | $162 |
| Hospital discharge day management, 30 minutes or less | 14 | $906 | $65 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 15 | $748 | $50 |
| Ultrasound of heart, follow-up | 30 | $739 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 38 | $732 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 37 | $479 | $13 |
| Ultrasound of heart blood flow, valves and chambers | 30 | $472 | $15 |
| Heart muscle strain imaging | 35 | $370 | $11 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 36 | $248 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 66 | $192 | $3 |
2021: 15 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 360 | $22,157 | $60 |
| Long return visit (40+ min) | 36 | $8,613 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,324 | $92 |
| New patient visit (60+ min) | 18 | $2,994 | $166 |
| Ultrasound of heart with probe in esophagus, with report | 30 | $2,737 | $91 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 32 | $2,247 | $70 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 35 | $2,057 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 32 | $1,936 | $60 |
| Ultrasound of heart, follow-up | 26 | $594 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 30 | $459 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 20 | $394 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $264 | $13 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 26 | $176 | $6 |
| Heart muscle strain imaging | 16 | $173 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 56 | $157 | $3 |
2020: 12 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 235 | $15,561 | $64 |
| Ultrasound of heart with probe in esophagus, with report | 32 | $3,132 | $98 |
| Long return visit (40+ min) | 17 | $2,330 | $101 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 25 | $1,809 | $72 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 22 | $1,275 | $58 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 17 | $1,006 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 36 | $768 | $20 |
| Ultrasound of heart, follow-up | 25 | $589 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 39 | $556 | $14 |
| Ultrasound of heart blood flow, valves and chambers | 31 | $521 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 54 | $161 | $3 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 24 | $160 | $6 |
2019: 12 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 502 | $31,964 | $62 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 53 | $3,314 | $61 |
| Ultrasound of heart with probe in esophagus, with report | 23 | $2,349 | $98 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 30 | $2,096 | $70 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 32 | $1,739 | $54 |
| Ultrasound of heart, follow-up | 46 | $1,061 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 51 | $960 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 51 | $654 | $13 |
| Ultrasound of heart blood flow, valves and chambers | 23 | $396 | $17 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 46 | $301 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 69 | $202 | $3 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 13 | $105 | $8 |
2018: 14 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 353 | $22,059 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,505 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,969 | $175 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $2,498 | $62 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 34 | $2,006 | $59 |
| Ultrasound of heart with probe in esophagus, with report | 19 | $1,693 | $89 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 54 | $898 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 93 | $707 | $7 |
| Ultrasound of heart, follow-up | 27 | $648 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 54 | $640 | $12 |
| Ultrasound of heart blood flow, valves and chambers | 19 | $304 | $16 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 27 | $184 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 45 | $128 | $3 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 15 | $109 | $7 |
2017: 13 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 299 | $15,826 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 448 | $4,949 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,384 | $93 |
| Long return visit (40+ min) | 30 | $2,799 | $82 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 38 | $2,196 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,990 | $181 |
| Ultrasound of heart with probe in esophagus, with report | 19 | $1,702 | $90 |
| Ultrasound of heart, follow-up | 45 | $1,069 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 36 | $465 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 19 | $365 | $19 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 56 | $362 | $6 |
| Ultrasound of heart blood flow, valves and chambers | 15 | $239 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 67 | $183 | $3 |
2016: 10 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 367 | $19,298 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 924 | $11,773 | $7 |
| Long return visit (40+ min) | 44 | $5,088 | $89 |
| New patient visit (60+ min) | 20 | $2,754 | $138 |
| Ultrasound of heart with probe in esophagus, with report | 22 | $2,219 | $101 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 40 | $2,211 | $54 |
| Ultrasound of heart, follow-up | 69 | $1,685 | $21 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 78 | $549 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 37 | $433 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 82 | $245 | $3 |
2015: 10 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 280 | $15,040 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 691 | $7,316 | $7 |
| Long return visit (40+ min) | 33 | $4,114 | $91 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 39 | $2,092 | $54 |
| Ultrasound of heart with probe in esophagus, with report | 18 | $1,817 | $101 |
| New patient visit (60+ min) | 12 | $1,573 | $131 |
| Ultrasound of heart, follow-up | 63 | $1,451 | $21 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 69 | $442 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 35 | $397 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 72 | $207 | $3 |
2014: 9 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 213 | $11,195 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 895 | $8,938 | $7 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 72 | $4,242 | $57 |
| Long return visit (40+ min) | 25 | $2,612 | $90 |
| Ultrasound of heart, follow-up | 70 | $1,569 | $21 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,478 | $87 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 69 | $822 | $12 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 87 | $577 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 84 | $261 | $3 |
2013: 11 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 205 | $10,187 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 538 | $5,375 | $7 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 62 | $3,648 | $55 |
| Long return visit (40+ min) | 20 | $1,874 | $89 |
| Ultrasound of heart, follow-up | 74 | $1,640 | $20 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,431 | $84 |
| New patient visit (60+ min) | 11 | $1,407 | $128 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 66 | $793 | $11 |
| Return visit (30+ min) | 12 | $768 | $64 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 79 | $522 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 83 | $285 | $3 |
Medicaid work
$22,820 in 2024
Medicaid paid $22,820 for 234 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 179 | $21,078 |
| Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography) | 43 | $1,092 |
| Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging) | 12 | $651 |
| 2024 | 234 | 3 | 34 | $22,820 |
| 2023 | 133 | 1 | 32 | $11,811 |
| 2022 | 183 | 1 | 32 | $13,714 |
| 2021 | 177 | 1 | 24 | $15,910 |
| 2020 | 98 | 1 | 16 | $10,343 |
| 2019 | 245 | 1 | 28 | $20,063 |
| 2018 | 217 | 2 | 50 | $11,283 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 133 | $11,811 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 183 | $13,714 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 177 | $15,910 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 98 | $10,343 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 245 | $20,063 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 162 | $10,821 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 55 | $462 |
Drugs they prescribed that Part D paid
$1,583,562
Pharmacies billed $1,583,562 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 497) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
250 generic and 247 brand-name prescriptions · $1,583,562 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Camzyos | 184 | $1,517,450 | $8,247 |
| Eliquis | 44 | $43,365 | $986 |
| Jardiance | 16 | $13,232 | $827 |
| Metoprolol | 56 | $1,097 | $20 |
| Candesartan Cilexetil | 35 | $1,084 | $31 |
See all 10 drugs
| Camzyos | 184 | $1,517,450 | $8,247 |
| Eliquis | 44 | $43,365 | $986 |
| Jardiance | 16 | $13,232 | $827 |
| Metoprolol | 56 | $1,097 | $20 |
| Candesartan Cilexetil | 35 | $1,084 | $31 |
| Spironolactone | 36 | $446 | $12 |
| Carvedilol | 18 | $343 | $19 |
| Atorvastatin | 12 | $178 | $15 |
| Losartan | 12 | $103 | $9 |
| Furosemide | 15 | $53 | $4 |
Year by year
| 2024 | 497 | 69 | 0% (0) | 50% | $1,583,562 |
| 2023 | 72 | 23 | 0% (0) | 38% | $153,528 |
| 2022 | 55 | 19 | 0% (0) | None | $9,906 |
| 2021 | 85 | 24 | 0% (0) | None | $5,308 |
| 2020 | 85 | 25 | 0% (0) | 16% | $10,667 |
| 2019 | 52 | 17 | 0% (0) | None | $3,980 |
| 2018 | 93 | 32 | None | 17% | $4,685 |
| 2017 | 109 | 29 | 0% (0) | 17% | $10,778 |
| 2016 | 106 | 28 | 0% (0) | 27% | $12,743 |
| 2015 | 59 | 24 | 0% (0) | 19% | $9,537 |
| 2014 | 56 | 11 | 0% (0) | 52% | $8,966 |
| 2013 | 15 | None | 0% (0) | None | $378 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Camzyos | 16 | $145,119 | $9,070 |
| Candesartan Cilexetil | 11 | $339 | $31 |
| Furosemide | 13 | $79 | $6 |
2022: 1 drug
| Candesartan Cilexetil | 12 | $1,485 | $124 |
2021: 3 drugs
| Metoprolol | 22 | $308 | $14 |
| Atorvastatin | 12 | $121 | $10 |
| Spironolactone | 11 | $78 | $7 |
2020: 1 drug
| Metoprolol | 23 | $431 | $19 |
2019: 1 drug
| Metoprolol | 13 | $467 | $36 |
2017: 3 drugs
| Metoprolol | 26 | $1,054 | $41 |
| Valsartan | 11 | $124 | $11 |
| Lisinopril | 11 | $20 | $2 |
2016: 4 drugs
| Eliquis | 14 | $6,242 | $446 |
| Metoprolol | 25 | $702 | $28 |
| Carvedilol | 11 | $77 | $7 |
| Clonidine | 16 | $75 | $5 |
2015: 1 drug
| Metoprolol | 16 | $914 | $57 |
2014: 2 drugs
| Metoprolol | 20 | $881 | $44 |
| Clonidine | 11 | $88 | $8 |
Money from drug and device companies
$466 in 2025
| 2025 | 1 | 5 | None | $466 |
| 2024 | 1 | 1 | None | $115 |
| 2023 | 1 | 2 | None | $9,611 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $466 | 5 payments
|
See all 5 published payments
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-27 | None | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-27 | None | $53 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-02-27 | None | $221 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-27 | None | $115 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-27 | None | $48 |
See earlier years (2024, 2023)
2024: $115
| E.R. Squibb & Sons L.L.C. | None | $115 | 1 payment
|
2023: $9,611
| E.R. Squibb & Sons L.L.C. | Camzyos | $9,611 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · Phase Iia Ohcm Pom (Part A) - A Phase 2a, Open-Label, Pilot Study To Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Myk-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract · 2023 | Their institution | $253,464 |
| E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed Maverick-Hcm Or Explorer-Hcm · 2021 | Their institution | $250,653 |
| E.R. Squibb & Sons, L.L.C. · Phaseii Aohcm Pom(Part A) - A Phase 2a, Open-Label, Pilot Study To Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Myk-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract O · 2024 | Their institution | $249,664 |
| E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed Maverick-Hcm Or Explorer-Hcm · 2022 | Their institution | $154,516 |
| E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten (Myk-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the Maverick-Hcm (Myk-461-006) Or Explorer-Hcm (Myk-461-005) Trails (Mava-Lte) · 2024 | Their institution | $129,916 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2a, Open-Label, Pilot Study To Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Myk-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (Mercutio) · 2025 | Their institution | $111,703 |
| E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten (Myk-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the Maverick-Hcm (Myk-461-006) Or Explorer-Hcm (Myk-461-005) Trails (Mava-Lte) · 2025 | Their institution | $107,633 |
| E.R. Squibb & Sons, L.L.C. · A Long-Term Safety Extension Study of Mavacamten (Myk-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the Maverick-Hcm (Myk-461-006) Or Explorer-Hcm (Myk-461-005) Trails (Mava-Lte) · 2023 | Their institution | $94,475 |
| E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2024 | Their institution | $68,659 |
| E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2025 | Their institution | $40,955 |
| Philips Electronics North America Corporation · Ecs Study · 2022 | Their institution | $29,552 |
| E.R. Squibb & Sons, L.L.C. · A Prospective Registry Study To Assess Real-World Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive Hcm) · 2024 | Their institution | $25,275 |
| GE HEALTHCARE · Influence of Hemodynamics on Myocardial Work · 2021 | Their institution | $23,888 |
| E.R. Squibb & Sons, L.L.C. · Mavacamten in Non-Obstructive Hcm · 2023 | Their institution | $23,788 |
| E.R. Squibb & Sons, L.L.C. · A Prospective Registry Study To Assess Real-World Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-Hcm) (Discover-Hcm) · 2025 | Their institution | $21,860 |
| E.R. Squibb & Sons, L.L.C. · A Prospective Registry Study To Assess Real-World Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive Hcm) · 2023 | Their institution | $11,190 |
| E.R. Squibb & Sons, L.L.C. · A Study To Evaluate the Efficacy, Safety, and Tolerability of Myk-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy · 2023 | This clinician | $9,889 |
| Philips North America LLC · Ecs Study · 2024 | Their institution | $4,900 |
| E.R. Squibb & Sons, L.L.C. · Deliver Insights on Safety in Hypertrophic Cardiomyopathy and Observe Endpoints in Real World (Discover-Hcm) · 2024 | Their institution | $4,396 |
| E.R. Squibb & Sons, L.L.C. · Nhcm Phase III - A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2023 | Their institution | $3,692 |
| E.R. Squibb & Sons, L.L.C. · A Study To Evaluate the Efficacy, Safety, and Tolerability of Myk-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (Mercutio) · 2024 | Their institution | $2,985 |
| E.R. Squibb & Sons, L.L.C. · A Study To Evaluate the Efficacy, Safety, and Tolerability of Myk-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy · 2023 | Their institution | $2,013 |
| E.R. Squibb & Sons, L.L.C. · A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (Odyssey-Hcm) · 2024 | Their institution | $1,165 |
| E.R. Squibb & Sons, L.L.C. · Phase Iia Ohcm Pom - A Phase 2a, Open-Label, Pilot Study To Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Myk-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruct · 2022 | Their institution | $199 |
| E.R. Squibb & Sons, L.L.C. · Mava Lte - A Long-Term Safety Extension Study of Mavacamten (Myk-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the Maverick-Hcm (Myk-461-006) Or Explorer-Hcm (Myk-461-005) Trials (Mava-Lte) · 2022 | Their institution | $176 |
| E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · 2023 | Their institution | $135 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1467427096
- Licence
- CA C147652, MD D60411California C147652: Current · expires 2028-05-31
- Group
- University of California San Francisco · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- MD 403643300, MN 338027100
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 505 Parnassus Ave # M314, San Francisco, CA, 94143
- NPI first listed
- 2006-02-17
- NPI last updated
- 2021-10-05
- NPI record certified
- 2021-10-05
This is when the NPI record was last certified, not a medical board exam.